BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 30, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/27 cls
Amgen (AMGN) Baird Christopher Raymond Other Neutral -1% $55.62
Banc of America Securities William Sargent Other Neutral
Raymond raised his FY07 EPS to $4.28 from $4.24 on AMGN's solid 2Q. However, he sees "significant uncertainty" with respect to the company's Aranesp/Epogen franchise (see "EPO Unloading," A9).
Sargent raised his FY07 and FY08 EPS estimates to $4.08 from $3.64 and to $4.17 from $3.58 to reflect expected cost control (see "EPS Watch," A18).
Amylin (AMLN) Banc of America Securities William Ho Price target Neutral 8% $46.90
Ho lowered his target to $44 from $46 after AMLN reported 2Q earnings. He also lowered his FY07 revenue guidance to $768M from $819M based on lower-than-expected Byetta sales (see "EPS Watch," A18).
Anadys (ANDS) Piper Jaffray Edward Tenthoff Downgrade Underperform (from market outperform) -38% $2.34
Tenthoff lowered his target to $2.50 from $5 after ANDS and partner Novartis (NVS; SWX:NOVN) discontinued development of ANA975 to treat chronic hepatitis C virus (HCV) infection. The prodrug of isatoribine, a toll-like receptor...

Read the full 1084 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >